MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients
Study Details
Study Description
Brief Summary
While many people with COVID-19 suffer from respiratory disease, there is growing evidence that the virus also affects other organs. The purpose of this study is to better understand the effects of COVID-19 on the lungs and other organs.
The study investigators have developed new techniques in Magnetic Resonance Imaging (MRI) to scan the lungs, heart, brain and liver. The study investigators hope to learn more about how the virus causes inflammation in these organs and how this inflammation changes over time as people recover from COVID-19 illness.
The study aims to enroll 228 people in Alberta. Participants will undergo one or more MRI scans and have blood testing at one or more time points to assess for inflammation, kidney function, liver function and possible heart injury. Participants will also undergo testing to assess sense of smell, cognition (thinking and memory), spirometry (breathing test for lung function) and and exercise tolerance (walk test).
The study investigators hope this study will help us learn more about the long-term risks of COVID-19 disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Participants with newly or recently diagnosed COVID-19 infection (inpatients and outpatients) will undergo multi-organ MRI (heart, brain, lungs, liver), blood work, and functional testing at one or more time points. Functional testing will include olfaction testing, cognitive testing, spiromety, and a walk test.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Troponin Substudy Participants with new COVID-19 infection will undergo high-sensitivity Troponin testing; participants with elevated Troponin will undergo MRI, bloodwork, and olfaction testing at Baseline, then repeat MRI, bloodwork and all functional testing at the Recovered (ie 12weeks post diagnosis) phase. Participants with normal Troponin will undergo only olfaction testing and bloodwork at baseline, then MRI, bloodwork and all functional testing at the Recovered phase. |
Diagnostic Test: MRI (heart, brain, lungs, liver)
MRI (heart, brain, lungs, liver)
Diagnostic Test: Bloodwork
Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
Other: Cognitive testing
NIH toolbox Cognitive Measures
Other: Olfaction testing
Brief Smell Identification Test (BSIT)
Diagnostic Test: Spirometry
Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
Other: Walk Test
Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
|
| Late Cross-Sectional Substudy Participants with a COVID-19 diagnosis at least 3 months prior to enrollment will undergo MRI, bloodwork and all functional testing at the Recovered phase only. |
Diagnostic Test: MRI (heart, brain, lungs, liver)
MRI (heart, brain, lungs, liver)
Diagnostic Test: Bloodwork
Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
Other: Cognitive testing
NIH toolbox Cognitive Measures
Other: Olfaction testing
Brief Smell Identification Test (BSIT)
Diagnostic Test: Spirometry
Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
Other: Walk Test
Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
|
Outcome Measures
Primary Outcome Measures
- Native myocardial T1 relaxation time [12 weeks post COVID-19 diagnosis]
Myocardial T1 is a surrogate marker of myocardial edema and the most sensitive MRI measure of acute myocarditis. We will show that myocardial T1 at baseline is significantly higher than myocardial T1 at 12 weeks follow-up. At 12 weeks, we will also compare native myocardial T1 in patients with baseline elevated troponin to those with baseline normal troponin as well as healthy controls
Secondary Outcome Measures
- FLAIR imaging [12 weeks post COVID-19 diagnosis]
Similar within group and between group comparisons of MRI derived lung water content, liver water content, and the presence of brain inflammation on FLAIR imaging
- Compare 12-week cognitive testing to the corresponding findings on MRI of brain, heart and lung at baseline [12 weeks post COVID-19 diagnosis]
Compare 12-week cognitive testing (NIH toolbox score) to the corresponding findings on MRI of brain, heart and lung at baseline
- Compare 12-week spirometry to the corresponding findings on MRI of brain, heart and lung at baseline [12 weeks post COVID-19 diagnosis]
Compare 12-week spirometry (FEV1, FVC and FEV1:FVC) to the corresponding findings on MRI of brain, heart and lung at baseline
- Compare 12-week walk test results to the corresponding findings on MRI of brain, heart and lung at baseline [12 weeks post COVID-19 diagnosis]
Compare 12-week walk test results (distance and time) to the corresponding findings on MRI of brain, heart and lung at baseline
- Compare 12-week cognitive testing in patients with normal smell and/or normal appearing brainstem on MRI to patients with no or impaired smell and/or injury to brainstem on MRI [12 weeks post COVID-19 diagnosis]
Compare 12-week cognitive testing in patients with normal smell and/or normal appearing brainstem on MRI to patients with no or impaired smell and/or injury to brainstem on MRI
- Compare MRI measures of organ dysfunction at 12-24 weeks in survivors according to severity of prior COVID-19 illness: (i) hospitalized, (ii) symptomatic, not hospitalized and (iii) asymptomatic [12-24 weeks post COVID-19 diagnosis]
Compare MRI measures of organ dysfunction at 12-24 weeks in survivors according to severity of prior COVID-19 illness: (i) hospitalized, (ii) symptomatic, not hospitalized and (iii) asymptomatic
Eligibility Criteria
Criteria
Troponin substudy Inclusion Criteria:
-
18 years of age or older
-
Willing and able to provide informed consent
-
COVID-19 positive test (within 14 days of positive test date)
-
High-sensitivity Troponin-I >100ng/L or Troponin T > 52ng/L
-
Ability to obtain Baseline MRI imaging within 7 days (up to 14 days maximum) of Troponin result
Troponin substudy Exclusion Criteria:
-
Contraindication to MRI or MRI contrast
-
GFR < 30ml/kg/min/1.73m2
-
Hemodynamic instability requiring inotropic agents
-
Active ventilatory support
Late cross-sectional substudy Inclusion Criteria:
-
18 years of age or older
-
Willing and able to provide informed consent
-
Previously diagnosed with COVID-19 > 3 months ago
-
Ability to obtain MRI imaging at minimum 12 weeks from COVID-19 diagnosis
Late cross-sectional substudy Exclusion Criteria:
- Contraindication to MRI or MRI contrast
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Calgary | Calgary | Alberta | Canada | |
| 2 | University of Alberta | Edmonton | Alberta | Canada |
Sponsors and Collaborators
- University of Alberta
- Canadian VIGOUR Centre
Investigators
- Principal Investigator: Ian Paterson, MD, University of Alberta
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Pro00102389